Treatment Patterns and Outcomes in Participants With Advanced Melanoma in Germany Using a German Database

Bristol-Myers Squibb (BMS)

Status: Completed

Conditions: Advanced Melanoma

Study type: Observational

Funder types: Industry

Identifiers

NCT05426239

CA209-8XH

Details and patient eligibility

About

This study is a non-interventional retrospective observational study performed on secondary data from a German multi-site cohort registry, the German national registry of skin cancer (ADOReg).

Enrollment: 1,008 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Signed informed consent for inclusion in ADOReg registry must be documented at study site
• Diagnosis of advanced (nonresectable or metastatic) melanoma in stage III or stage IV
• Participants received any systemic therapy to treat the advanced melanoma
• First-line systemic treatment was initiated within the index window (19-Jun-2015 to 30-Jun-2018)

Exclusion criteria

• Age <18 years at index date
• Receipt of clinical trial study drug at any time

Trial design

1,008 participants in 1 patient group

Cohort 1

Description:

Participants initiating first-line systemic therapy to treat advanced melanoma.